TC-325 hemostatic powder in the management of upper gastrointestinal malignant bleeding: a randomized controlled trial

Abstract

Background and study aims Upper gastrointestinal bleeding (UGIB) from malignancy is associated with high rebleeding and mortality rates. Recently, TC-325 powder has shown promising results in the treatment of UGIB, including malignant bleeding. The aim of this study was to compare the efficacy of TC-325 versus best clinical management.

Patients and methods From August 2016 to February 2020, all patients with evidence of UGIB from malignancy were randomized to receive TC-325 therapy or control group, in which endoscopic treatment was not mandatory. Exclusion criteria were hemoglobin drop without overt bleeding and UGIB from non-tumor origin. The primary outcome was 30-day mortality. Secondary outcomes were 30-day rebleeding, blood transfusion and length of hospital stay.

Results Sixty-two patients were randomized, three were excluded and 59 were included in the final analysis (TC-325 group = 28; control = 31). Groups were similar at baseline. Active bleeding was observed in 22 patients in the TC-325 group and 19 in the control group (P = 0.15). Successful initial hemostasis with TC-325 was achieved in all cases. Additional therapy (radiotherapy, surgery or arterial embolization) was equally performed in both groups (42.9 % vs 58.1 %; P = 0.243). There were no differences in 30-day mortality (28.6 % vs. 19.4 %, P = 0.406) or 30-day rebleeding rates (32.1 % vs. 19.4 %, P = 0.26). Logistic regression identified no significant predictors of rebleeding. Age, Eastern Cooperative Oncology Group (ECOG) score 3 to 4 and AIMS65 score > 1 predicted greater mortality.

Conclusions TC-325 was effective in achieving immediate hemostasis in malignant gastrointestinal bleeding but did not reduce 30-day mortality, 30-day rebleeding, blood transfusion or length of hospital stay. Age, ECOG 3–4, and AIMS65 > 1 were predictive factors of mortality.

Publikationsverlauf

Eingereicht: 30. Januar 2022

Angenommen nach Revision: 20. Juli 2022

Accepted Manuscript online:
21. Juli 2022

Artikel online veröffentlicht:
17. Oktober 2022

• References

• 1 Maluf-filho F, Martins BC, De Lima MS. et al. Etiology, endoscopic management and mortality of upper gastrointestinal bleeding in patients with cancer. United Eur Gastroenterol J 2013; 1: 60-67
• 2 Loftus EV, Alexander GL, Ahlquist DA. et al. Endoscopic treatment of major bleeding from advanced gastroduodenal malignant lesions. Mayo Clin Proc 1994; 69: 736-740
• 3 Savides TJ, Jensen DM, Cohen J. et al. Severe upper gastrointestinal tumor bleeding: endoscopic findings, treatment, and outcome. Endoscopy 1996; 28: 244-248
• 4 Chen YI, Wyse J, Lu Y. et al. TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2020; 91: 321-328.e1
• 5 Martins BC, Wodak S, Gusmon CC. et al. Argon plasma coagulation for the endoscopic treatment of gastrointestinal tumor bleeding: A retrospective comparison with a non-treated historical cohort. United Eur Gastroenterol J 2016; 4: 49-54
• 6 Mathus-Vliegen EMH, Tytgat GNJ. Analysis of Failures and complications of neodymium: YAG laser photocoagulation in gastrointestinal tract tumors. Endoscopy 1990; 22: 17-23
• 7 Heller SJ, Tokar JL, Nguyen MT. et al. Management of bleeding GI tumors. Gastrointest Endosc 2010; 72: 817-824
• 8 Ahn D, Lee SH, Park YS. et al. Hemostatic efficacy and clinical outcome of endoscopic treatment of Dieulafoyʼs lesions : comparison of endoscopic hemoclip placement and endoscopic band ligation. YMGE 2012; 75: 32-38
• 9 Aziz M. Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding: a systematic review with meta-analysis. Ann Gastroenterol 2020;
• 10 Mutneja HR, Bhurwal A, Go A. et al. Efficacy of hemospray in upper gastrointestinal bleeding: a systematic review and meta-analysis. J Gastrointest Liver Dis 2020; 29: 69-76
• 11 Shin J, Cha B, Park J-S. et al. Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding. BMC Gastroenterol 2021; 21: 40
• 12 Kim Y, Park J, Kim E. et al. Hemostatic powder application for control of acute upper gastrointestinal bleeding in patients with gastric malignancy. Endosc Int Open 2018; 06: E700-E705
• 13 Pittayanon R, Prueksapanich P, Rerknimitr R. The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor. Endosc Int open 2016; 4: E933-E936
• 14 Pittayanon R, Rerknimitr R, Barkun A. Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. Gastrointest Endosc 2018; 87: 994-1002
• 15 Chen Y-I, Barkun AN. Hemostatic powders in gastrointestinal bleeding. Gastrointest Endosc Clin N Am 2015; 25: 535-552